Table 3.
Comparison of demographic and clinical characteristics between TAD-subjects and Non-transfused controls*
| Characteristic | Transfused cohort (n=139) | Controls (n=267) | p-value |
|---|---|---|---|
| Age category (years) (n, %) | 0.99 | ||
| 0–2 | 36 (25.9%) | 69 (25.8%) | |
| >2–5 | 29 (20.9%) | 55 (20.6%) | |
| >5–13 | 21 (15.1%) | 41 (15.4%) | |
| >13 | 53 (38.1%) | 102 (38.2%) | |
| PELOD-2 | |||
| Mean (SD) | 4.9 (2.7) | 4.5 (2.5) | 0.15 |
| ICU day | |||
| Mean (SD) | 2.1 (1.6) | 2.0 (1.4) | 0.53 |
| Opiate exposure (n, %) | 0.97 | ||
| yes | 94 (67.6%) | 181 (67.8%) | |
| no | 45 (32.4%) | 86 (32.2%) | |
| Benzodiazepine exposure (n, %) | 0.98 | ||
| yes | 71 (51.1%) | 136 (50.9%) | |
| no | 68 (48.9%) | 131 (49.1%) | |
| Outcome: Cognitive status within three days (n, %) | <0.001 | ||
| delirium/coma | 103 (74.1%) | 115 (43.1%) | |
| DFCF | 36 (25.9%) | 152 (56.9%) | |
*
matched for day of randomization in TAD-subjects
[DFCF: delirium-free/coma-free; PELOD-2: Pediatric Logistic Organ Dysfunction-2 score]